Nura Bio closes Series A financing with $68m in new funds
Company announces successful completion of Phase 1 study of NB-4746, Nura Bio’s brain-penetrant SARM1 inhibitor
A leading resource for the Pharmaceutical industry since 2002
Company announces successful completion of Phase 1 study of NB-4746, Nura Bio’s brain-penetrant SARM1 inhibitor